Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/49542
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Estrogen therapy for Hereditary Haemorrhagic Telangiectasia (HHT): Effects of Raloxifene, on Endoglin and ALK1 expression in endothelial cells |
Autor: | Albiñana, Virginia CSIC; Bernabeu Herrero, María Elvira; Zarrabeitia, Roberto; Bernabéu, Carmelo CSIC ORCID ; Botella, Luisa María CSIC ORCID | Palabras clave: | Raloxifene HHT Endoglin Epistaxis ALK1 |
Fecha de publicación: | mar-2010 | Editor: | Schattauer | Citación: | Thrombosis and Haemostasis 103(3):525-534(2010) | Resumen: | Hereditary haemorrhagic telangiectasia (HHT), or Rendu-Osler-Weber syndrome, is an autosomal dominant vascular disease. The clinical manifestations are epistaxis, mucocutaneous and gastrointestinal telangiectases, and arteriovenous malformations. There are two predominant types of HHT caused by mutations in Endoglin (ENG) and activin receptor-like kinase 1 (ALK1) (ACVRL1) genes, HHT1 and HHT2, respectively. No cure for HHT has been found and there is a current need to find new effective drug treatments for the disease. Some patients show severe epistaxis which interferes with their quality of life. We report preliminary results obtained with Raloxifene to treat epistaxis in postmenopausal HHT women diagnosed with osteoporosis. We tried to unravel the molecular mechanisms involved in the therapeutic effects of raloxifene. ENG and ACVRL1 genes code for proteins involved in the transforming growth factor β pathway and it is widely accepted that haploinsufficiency is the origin for the pathogenicity of HHT. Therefore, identification of drugs able to increase the expression of those genes is essential to propose new therapies for HHT. In vitro results show that raloxifene increases the protein and mRNA expression of ENG and ALK1 in cultured endothelial cells. Raloxifene also stimulates the promoter activity of these genes, suggesting a transcriptional regulation of ENG and ALK1. Furthermore, Raloxifene improved endothelial cell functions like tubulogenesis and migration in agreement with the reported functional roles of Endoglin and ALK1. Our pilot study provides a further hint that oral administration of raloxifene may be beneficial for epistaxis treatment in HHT menopausal women. The molecular mechanisms of raloxifene involve counteracting the haploinsufficiency of ENG and ALK1 | Descripción: | 20 p.-7 fig. | Versión del editor: | http://dx.doi.org/10.1160/TH09-07-0425 | URI: | http://hdl.handle.net/10261/49542 | DOI: | 10.1160/TH09-07-0425 | ISSN: | 0340-6245 |
Aparece en las colecciones: | (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Throm. & Haem.FIGURAS (2010).ppt | 1,49 MB | Microsoft Powerpoint | Visualizar/Abrir | |
Throm. & Haem. 2010.doc | 142 kB | Microsoft Word | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
62
checked on 18-abr-2024
WEB OF SCIENCETM
Citations
62
checked on 27-feb-2024
Page view(s)
446
checked on 23-abr-2024
Download(s)
270
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.